Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02784171
Title Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

malignant pleural mesothelioma

Therapies

Cisplatin + Pemetrexed Disodium

Pembrolizumab

Age Groups: senior | adult
Covered Countries ITA | FRA | CAN


No variant requirements are available.